RxDoctor Payments Data

John Root, MD

Family Medicine · Rockport, TXNPI 1871589341

Payments from drug & device makers

$571in general payments, 2019–2025

Across 35 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$89
  • Lilly USA, LLC$80
  • Novo Nordisk$70
  • Pfizer$56
  • Boehringer Ingelheim$55
  • Amgen$49
  • plus $172 from 8 others

What the payments were for

  • Food & beverage$571100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$571 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$20,554
Medicare patients
112
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin176$287,560
OzempicSemaglutide124$148,947
EliquisApixaban139$133,102
Trelegy ElliptaFluticasone/Umeclidin/Vilanter125$127,601
TrulicityDulaglutide57$82,826
Bydureon BciseExenatide Microspheres55$78,947
XareltoRivaroxaban32$34,826
MounjaroTirzepatide31$34,164
JanuviaSitagliptin Phosphate13$23,723
SymbicortBudesonide/Formoterol Fumarate56$22,799
Breo ElliptaFluticasone/Vilanterol21$21,816
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$21,802
FarxigaDapagliflozin Propanediol14$20,909
MyrbetriqMirabegron25$19,271
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$15,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$55$315,176206 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$36$167,945189 claims
Novo NordiskOzempic$70$148,947124 claims
PfizerEliquis$56$133,102139 claims
Lilly USA, LLCTrulicity, Mounjaro$80$116,99088 claims
AstraZenecaSymbicort, Farxiga, Breztri Aerosphere, Brilinta$11$64,95495 claims
MerckJanuvia$11$23,72313 claims
Sanofi-aventis U.S. LLCLantus$89$4,31917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Rockport

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →